Searchable abstracts of presentations at key conferences in endocrinology

ea0035p550 | Endocrine tumours and neoplasia | ECE2014

The effectiveness of yttrium90/lutetium177-labeled somatostatin analogues treatment in functional pNETs

Michalik Barbara , Handkiewicz-Junak Daria , Hasse-Lazar Kornelia , Jarzab Barbara

Introduction: Therapy with somatostatin analouges is usually ineffective to remove hormonal symptoms in patients with functional pancreatic neuroendocrine tumors (pNET). Alternative treatment modalities, to control symptoms of excessive hormonal production, are necessary. Thus, the aim of our study was to evaluate results of radiopeptide treatment in patient with functional pNET.Materials and methods: 92 patients with pNET (49 women and 43 men, median ag...

ea0056p127 | Endocrine tumours and neoplasia | ECE2018

Adrenocortical cancer – the effectiveness of mitotane therapy depending on the time of therapy and the therapeutic dose

Stepinski Kamil , Jurecka-Lubieniecka Beata , Michalik Barbara , Szpak-Ulczok Sylwia , Soczomski Przemyslaw , Jarzeb Barbara

Introduction: Mitotane-o’p-DDD belongs to insecticides (DDT pesticide contamination), it is the only drug registered by the FDA in treatment in adrenocortical carcinoma (ACC). Treatment effect is controled by mitotane concentration in the blood.Aim: The aim of the study is to evaluate the effectiveness of mitotane treatment in patients with adrenocortical cancer.Material and methods: We retrospectively reviewed data on ACC pat...

ea0049ep349 | Endocrine tumours and neoplasia | ECE2017

Parathyroid cancer – clinical presentation, prognostic factors and long-term evolution

Jurecka-Lubieniecka Beata , Michalik Barbara , Bula Grzegorz , Gawrychowski Jacek , Kajdaniuk Dariusz , Marek Bogdan , Tukiendorf Andrzej , Jarzab Barbara

Background: Parathyroid carcinoma (PC) is a rare endocrine malignancy affecting 0.5–5% of all patients with primary hyperparathyroidism. Due to the rarity of PC there is still lack of prognostic implications of the disease and clear consensus regarding management. Our purpose was to evaluate prognostic factors and treatment outcomes of patients treated at the Department of Nuclear Medicine and Endocrine Oncology.Methods: The target group covered 44 ...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0035p540 | Endocrine tumours and neoplasia | ECE2014

Monitoring of pheochromocytomas development in proto-oncogene RET mutation’s carriers

Kotecka-Blicharz Agnieszka , Jurecka-Lubieniecka Beata , Michalik Barbara , Pawlaczek Agnieszka , Oczko-Wojciechowska Malgorzata , Hasse-Lazar Kornelia , Jarzab Barbara

Proto-oncogene RET encodes a receptor tyrosine kinase. Germline point mutations of RET result in development of multiple endocrine neoplasia, type 2 (MEN 2). MEN 2 phenotype is correlated with intragene localization of germline mutation. The disease has three main subtypes, MEN 2A, MEN 2B and FMTC. Each of subtypes is associated with high risk of medullary thyroid cancer, MEN 2A and MEN 2B with 50% risk of pheochromocytoma, MEN 2A with 15–30% risk of primary hyperparathyr...

ea0070ep2 | Adrenal and Cardiovascular Endocrinology | ECE2020

Pregnancy during adjuvant mitotane therapy because of adrenocortical carcinoma – case report

Stępiński Kamil , Jurecka-Lubieniecka Beata , Michalik Barbara , Gorki Karolina , Jarząb Barbara

Introduction: Primary adrenocortical carcinoma (ACC) is a highly malignant but rare neoplasm. It can occur as a hormonally active or an inactive tumor. It is considered that about three-fourths of ACC cases are hormonally active, although they do not always give clinical symptoms. Mitotane (Lysodren) is registered by the FDA for the therapy of ACC, either for monotherapy or as a combined chemotherapy.Case report: A 34-year-old woman, with a histopatholog...

ea0020p239 | Bone/Calcium | ECE2009

The results of cinacalcet therapy in patients with severe or refractory hypercalcemia due to primary hyperparathyroidism

Krajewska Jolanta , Paliczka-Cieslik Ewa , Krawczyk Aleksandra , Szpak-Ulczok Sylwia , Michalik Barbara , Hasse-Lazar Kornelia , Jurecka-Lubieniecka Beata

Refractory or severe hypercalcemia is important clinical problem as it can lead to serious complications such as arrhythmias, acute or chronic pancreatitis, gastric ulcer, water and electrolyte balance disturbances, osteoporosis, psychoses and even to hypercalcemic crisis. Most often it is diagnosed in parathyroid cancer (PC). It is also observed in benign primary hyperparathyroidism (HPTH) in case of difficulties with adenoma’s localization. Routinely treatment includes ...

ea0063ep8 | Adrenal and Neuroendocrine Tumours | ECE2019

Characteristics of factors affecting the survival of patients with adrenal cortical carcinoma treated with mitotane

Stępiński Kamil , Jurecka-Lubieniecka Beata , Michalik Barbara , Kotecka-Blicharz Agnieszka , Gawlik Tomasz , Soczomski Przemysław , Jarzęb Barbara

Introduction: Adrenal cortical carcinoma (ACC) is a rare malignant neoplasm of epithelial origin, derived from the adrenal cortex, with a high tendency to local invasion and distant metastases.Aim: The aim was to assess the effect of serum mitotane concentration during mitotane therapy and identify prognostic factors on the survival of ACC patients.Material and methods: It was a multifactorial analysis of patients from a single end...

ea0070aep923 | Thyroid | ECE2020

Adverse effects of tyrosine kinase inhibitors in advanced thyroid carcinoma – a summary of 10-year experience

Krajewska Jolanta , Kukulska Aleksandra , Paliczka-Cieslik Ewa , Gawlik Tomasz , Olczyk Tomasz , Ledwon Aleksandra , Michalik Barbara , Kropinska Aleksadra , Handkiewicz-Junak Daria , Jarzab Barbara

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...

ea0063p421 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

RET Y791F carriers’ medical history – experience from one center

Hasse-Lazar Kornelia , Kotecka-Blicharz Agnieszka , Oczko-Wojciechowska Małgorzata , Pawlaczek Agnieszka , Michalik Barbara , Gawlik Tomasz , Jurecka-Lubieniecka Beata , Krajewska Jolanta , Krol Aleksandra , Legutko Marta , Czarniecka Agnieszka , Zeman Marcin , Jarzęb Barbara

Introduction: Germline mutations of RET oncogene result in development of multiple endocrine neoplasia type 2 (MEN 2). There is a strong correlation between type of the RET sequence changes and the aggressiveness of main syndrome feature, medullary thyroid carcinoma (MTC), and the incidence of remaining manifestations, mainly pheochromocytoma (PHEO). For many of the RET germline mutations, the clinical risk have been precisely defined, but there are ...